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~ Inhibition of  Atherosclerasis and Xanthoma 
Formation by L-Arginine In Cholesterol-Fed LDL 
Receptor Knockout Mice 
Walif Aji, Stefano Ravalli, Xian. oheng Jiang, Robed Michler, Paul 
J. Cannon. Columbia University, New York, NY 
To fnvestigale antialherosclarotic actions of nitric oxide (NO), experiments 
were performed in 4 groups of mica (n = 51group) lacking functional LDL 
receptor genes (LDLR-ko). Group 1 was fed a regular chow diet. Groups 2 to 
4 were fed a 1.25% high cholesterol Paigen diet; in addition, group 3 received 
supplemental L-arginine (at'g) and group 4 received arg plus L-nitre arginine 
(LNA), ~n inhibitor of NO synthase. Animals were sacrificed at 6 months; 
heads and sodas were removed and stained with oil-Red O for planimetry. 
Cholesterol was markedly increased in all animals on the high eholestarel 
diet compared to controls. Lipid profiles were similar in groups 2--4. Xan- 
thomas appeared in mice fed the high cholesterol diet and in those fed the 
high cholesterol di3t plus arg and LNA but not in the controls or In mice 
given arg. The mean atherosclerotic area was reduced significantly in the 
cholesterol-fed LOLR-ko mica given supplemental rg in comparison to those 
receiving the high cholesterol diet alone 0"able). 
Group Chow High Chol arg arg + LNA 
Lesion area/~2 0 797,053 419,651 1,161,833 
P < 0.005 Student Host 
The data indicate that arg supplementation i hibits atharosolerosis and 
xanthoma fon~allon in LDLR-ko mice on a high cholesterol diet. The fact that 
LNA abrogated these etfects suggests that the actions of arg are mediated 
by NO synthase. The data raise the possibility that arg may ba beneficial in 
patients with familial hyperchotssterolemia. 
• First With Chronic Platelet GPllb/llla Experience 
Receptor Blockade: A Pilot Study of  Xemloflban 
an Orally Active Antagonist In Unstublo Angina 
Patients Eligible for  PTCA 
Conrad Simpfendorfer, Kandica Kottke-Marchant, Eric J. Topoi. The 
Cleveland Clinic Foundation, Cleveland OH 
Although GPIIb/itla blockage has considerable promise in ischemlo head 
disease, them has been no experience with oral sustained inhibition to date. 
We performed a placebo controlled pilot study to evaluate the safety and 
pharmacodynamic response of Xemlofiban (X) administered orally (25 mg 
lid) for one month in patients with unstable angina undergoing PTCA. Of 23 
pts entered into the study, 15 were randomized to receive X and 8 to placebo 
(PI). Of 15 pts on X, 4 were withdrawn dudng the initial hospitalization: 
groin hematoma (n:2), slant implantation (n:l) and severe GI bleeding (n:l). 
Two subjects withdrew later because of rectal bleeding. Of the 9 pts who 
completed the study, 8 reported minor bleeding events. Pharmacodynamlc 
studies showed rapid onset, profound and sustained inhibition of pletelet 
aggregation compared to aspirin. 
Ptetelet Aggregation (%) 
Pro 2 Hrs post 2 Weeks 4 Weeks 
PL X PL x PL X PL X 
AOP(20/AM) 634-28 684-21 684-32 264-33 544-32 64-6 664-34 184-29 
Collagen (4 ~glml) 51±31 474-28 594-33 204-29 364-31 64-2 544-37 18:1:22 
Conclusion: Xemloflban given "Jrelly results in potent inhibition of platelet 
aggregation for a perind up to one m~nth. Minor bleeding events are common. 
Severe bleeding in 1 pts was associated with prolonged elimination of the 
drug. This aspect deserves fudher study. 
• Transforming Growth Factor-Betu I induces the 
Expression of  Vitronectln In Smooth Muscle Cells 
David C. Sane, Anita A. Pifts, Michael A. Kutchar, Gregory A. Breden. The 
Bowman Gray School of Medicine, Wake Forest Univ., Winston Salem, NC 
Vitronectin (VN), an extracoIlular metdx adhesive protein, regulates the co- 
agulation, complement, immune and fibrinolylic systems. VN can potentially 
alter the growth of the neointima by its ability to act as a haptotasttc factor 
for smooth muscle coils (SMC), its ability to prolong the activity of ftlmmbin, 
and its stabilization of plasminogen activator inhibitor-1. We have shown that 
vitronectin is present in athemscteretio and restenotto coronary arteries by 
performing immunohietochamietry of coronary artery sections and alherec- 
tomy samples. Using RT.PCR, we have further shown that vitrenastin Is 
expmssad by coils within the vessel wall, rather than merely being deposited 
from plasma. Based on its distribution, we hypothesized that VN was ex- 
pressed by SMC. SMC were cultured until confluent, then saturn-starved 
them for 3 days, prior to incubation with vehicle (unstimulated), TGF-,81 (10 
ng/ml), <f-thmmbin (20 nM) or basic FGF (10 ng/ml) for t.8 hours. Total RNA 
was harvested, treated with DNAse, then used for cDNA synthesis with AMV 
reverse transcriptase and oligo dT pdming. Specific pdmers for VN were 
used for PCR. Using the RT-PCR method, there was no VN expression in 
unstimulated or bGGF-etimulated cells and only a faintly detectable band with 
e-thin,bin stimulation, in contrast, TGF-/31 clsady produced a marked in- 
duction of vitronectin expression in the SMC. In conclusion, the expression of 
VN is induced by TGF-81 in smooth muscle co,s, probebly explaining its ori- 
gin in athemsclerotio and restenolfo coronary arteries. Vitronectin expressed 
by SMC in the vessel wall may contribute to neointimal growth. 
~ Reduodon of  Cyclic Flow Variat ions by 
Endothel ln B Receptor St imulation Is Mediated by 
Nitric Oxide In Rat Mecenterlc Artery Model 
Kenlcht FuJise, Lowell ~-'lacy, Pamela Beck, James 1". Wittereon, 
Tommy Brock. University of Texas Health Science Center at Houston, Texas 
Heart Institute and Texas Biotechnology Corporation, Houston TX 
Background: Cyclic flow variations(CFVs) represent repetitive cyc:es of 
pletelet adherence-aggregation, followed by dislodgement of platole~ thmmbi 
and restoration of blood flow at the site of vascular injury. W~ have shown 
that endothalin A receptor blockage reduces and endothelin B receptor (ETB) 
b~ockage promotes CFVs in rat mosentsdc artery modal. Since ETB stim- 
ulation leads to nitric oxide (NO) release from vascular endothelial cells, 
we hypothesized that effect of ET on CFVs is mediated by NO. Method: 
Male Wlstar rats (250-274 g) were anesthetized with pentobarbital. The aide 
branch of mesenteric artery (200-350/~m) was connulated with a polyethy- 
lene catheter. A short segment of artery was mechanically injured. CFVs 
and % luminal etenosis were recorded using intravital microscopy. After 20 
minutes of saline infusion (1 ulJmin, base line phase), saline (negative con- 
trol, n = 8) or Sarafotoxin S6C {S6C, 10 ng/mL, ETB agonist, N = 12) was 
infused for 20 rain (1 uUmin, interventional phase). Six rats with S6C also 
had [--NAME (Nitric oxide synthesis Inhibitor, 10 -s M) supeffused over the 
vessel segment. This was followed by a second saline infusion for 20 mln 
(recovery phase). The % changes of CFVs were calculated. Result: While 
saline infusion did not change CFVs (0.8 4. 4.6% SE), $6C infusion reduced 
the CFVs by 26.5 4. 10°/= (p < 0.05 compared with saline control). Suportu- 
sion of L-NAME not on~; abolished the eifact of $6C but tsnded to increase 
the CFVs (15.9 4. 6.6%, p > 0.3 compared with saline control). Conclusion: 
ETB stimulation reduces CFVs through nitric oxide synthesis since its effect 
Is abolished by L-NAME, nitric oxide synthesis inhibitor. 
~ BIphaelc Mural Proteolysls in Atherogenesls 
David J. Schneider, Michael A. Riccl, Burton E. SobeL University of 
Vermont, Burlington, VT 
Plasmlnogen activators (PAs, tissue type It-PAl and urol',lnaso type [u-PAl) 
end their primary Inhibitor (type 1 [PAl-l]) mw modulate progression of 
alherngenesis by facilitating accumulation and degradation of extracellular 
matrix. In this study, we determined the tissue content of PAS and PAl- 
1 in paired samples of normal and alheroscleretic artedes from the same 
patient. The tissue obtained dudng surgery and maintained in organ culture 
demonstrated viability by continued protein and DNA synthesis. Nter culture, 
protein was extracted and analyzed by ELISA for content of t-PA, u-PA, and 
PAl-1. In the tlrst pair, a fatty streak waa compared with adjacent 'nomlal' 
tissue from an aorta. PAl-1 content was increased by 15.6 rig/rag tissue 
protein (pint) and PA content was decreased by 0.6 ng/prot in the fatty streak. 
The second pair comprised a pop,teal artery segment with 50% stsnosis 
end a 'normal' branch of the same vessel. PAl-1 content was decreased by 
11.9 ng/pmt and PA content was increased by 0.44 ng/prot. The third pair 
comprised a superficial femoral artery segment with a > SOY= etenosls and a 
'normal' collateral. PAl-1 content was increased by 8.6 ng/Icret and PA content 
was increased by 1.13 ng/prot consistent with increase PA content seen in 
severely diseased adedes (> 80% stenosls) compared with 'normal' arteries 
(diseased PAs = 4.9 ~- 1.7, n = 10; 'normal' PAs = 0.9 4. 0.2 n = 8; ng/pret, 
p < 0.02). Thus, decreased mural proteolysls in early athemsclerosle mw 
potentiate xtracellular matrix accumulation and the subsequent increased 
mural proteolysls in moderate and severe etharosclerosls may be a marker 
of or potentiate migration of macmphages and smooth muscle cells. 
